Bolt Biotherapeutics, Inc. (BOLT)
USD 0.5
(-5.89%)
USD 0.5
(-5.89%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -69.52 Million | -76.5 Million | -57.06 Million | -47.3 Million | -26.34 Million | -9.87 Million |
| Net Income | -69.19 Million | -88.09 Million | -98.59 Million | -60.72 Million | -30.48 Million | -11.58 Million |
| Depreciation & Amortization | 1.88 Million | 1.66 Million | 1.19 Million | 611 Thousand | 335 Thousand | 302 Thousand |
| Deferred income taxes | 3.41 Million | - | 2.76 Million | 34 Thousand | - | - |
| Stock-based compensation | 9.22 Million | 9.57 Million | 8.5 Million | 1.42 Million | 508 Thousand | 123 Thousand |
| Change in working capital | -9.86 Million | -3.05 Million | 20.5 Million | -2.28 Million | 2.26 Million | 1.13 Million |
| Other non-cash items | -4.98 Million | 3.4 Million | 8.56 Million | 13.63 Million | 1.03 Million | 153 Thousand |
| Investing Cash Flow | 71.03 Million | 57.86 Million | -232.2 Million | -20.59 Million | -508 Thousand | -290 Thousand |
| Investments in PPE | -206 Thousand | -1.95 Million | -2.33 Million | -3.26 Million | -508 Thousand | -290 Thousand |
| Acquisitions | -71.24 Million | -59.81 Million | 229.86 Million | 17.33 Million | - | - |
| Investment purchases | -164.98 Million | -180.7 Million | -313.37 Million | -33.22 Million | - | - |
| Sales/Maturities of investments | 236.23 Million | 240.51 Million | 83.51 Million | 15.89 Million | - | - |
| Other Investing Activities | 71.24 Million | 59.81 Million | -229.86 Million | -17.33 Million | - | - |
| Financing Cash Flow | 253 Thousand | 503 Thousand | 311.1 Million | 39.59 Million | 48.62 Million | 19.09 Million |
| Debt repayment | - | - | - | - | -40 Thousand | -39 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | 13.63 Million | - | - | - |
| Common Stock Issuance | 253 Thousand | 503 Thousand | 311.1 Million | 294 Thousand | 72 Thousand | 20 Thousand |
| Other Financing Activities | 253 Thousand | 503 Thousand | 311.1 Million | 39.3 Million | 48.59 Million | 19.11 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -3.41 Million | 2.76 Million | 6.67 Million | 2.88 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -6.45 Million | -5.82 Million | 13.83 Million | -5.16 Million | 2.26 Million | 1.13 Million |
| Cash at beginning of period | 9.24 Million | 28.94 Million | 7.1 Million | 35.41 Million | 13.63 Million | 4.7 Million |
| Cash at end of period | 10.81 Million | 10.8 Million | 28.94 Million | 7.1 Million | 35.41 Million | 13.63 Million |
| Capital Expenditure | -206 Thousand | -1.95 Million | -2.33 Million | -3.26 Million | -508 Thousand | -290 Thousand |
| Effect of forex changes on cash | -200 Thousand | - | - | - | - | - |
| Net cash flow / Change in cash | 1.56 Million | -18.13 Million | 21.84 Million | -28.3 Million | 21.77 Million | 8.93 Million |
| Free Cash Flow | -69.73 Million | -78.45 Million | -59.4 Million | -50.57 Million | -26.85 Million | -10.16 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -21.19 Million | -10.81 Million | -69.19 Million | -17.9 Million | -16.25 Million | -18.05 Million |
| Depreciation & Amortization | 457 Thousand | 458 Thousand | 1.88 Million | 497 Thousand | 462 Thousand | 458 Thousand |
| Deferred income taxes | - | - | 3.41 Million | -3.06 Million | -1.33 Million | -1.11 Million |
| Stock-based compensation | 2.82 Million | 2.3 Million | 9.22 Million | 2.06 Million | 2.32 Million | 2.35 Million |
| Change in working capital | 1.77 Million | -8.44 Million | -9.86 Million | 1.53 Million | -2.69 Million | 518 Thousand |
| Other non-cash items | 3.73 Million | 2.95 Million | -4.98 Million | 2.59 Million | 744 Thousand | 731 Thousand |
| Investing Cash Flow | 18 Million | 10.2 Million | 71.03 Million | 15.8 Million | 12.65 Million | 13.58 Million |
| Investments in PPE | - | - | -206 Thousand | -6000.00 | -165 Thousand | -32 Thousand |
| Acquisitions | - | - | -71.24 Million | 55.42 Million | -12.82 Million | -13.61 Million |
| Investment purchases | -32.22 Million | -23.05 Million | -164.98 Million | -32.15 Million | -36.3 Million | -53.64 Million |
| Sales/Maturities of investments | 50.22 Million | 33.26 Million | 236.23 Million | 47.97 Million | 49.12 Million | 67.25 Million |
| Other Investing Activities | 18 Million | 10.2 Million | 71.24 Million | -1.00 | 12.82 Million | 13.61 Million |
| Financing Cash Flow | 79 Thousand | - | 253 Thousand | 106 Thousand | - | 147 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 79 Thousand | - | - | -141 Thousand | - | - |
| Common Stock Issuance | 79 Thousand | - | 253 Thousand | 106 Thousand | - | 147 Thousand |
| Other Financing Activities | 79 Thousand | - | 253 Thousand | 106 Thousand | - | 147 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -3.54 Million | -3.41 Million | 3.19 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.77 Million | -8.44 Million | -6.45 Million | 1.53 Million | -2.69 Million | 518 Thousand |
| Cash at beginning of period | 4.26 Million | 10.81 Million | 9.24 Million | 9.16 Million | 15.01 Million | 16.4 Million |
| Cash at end of period | 6.2 Million | 4.26 Million | 10.81 Million | 10.81 Million | 10.92 Million | 15.01 Million |
| Capital Expenditure | - | - | -206 Thousand | -6000.00 | -165 Thousand | -32 Thousand |
| Effect of forex changes on cash | - | - | -200 Thousand | 14.35 Million | - | -14.35 Million |
| Net cash flow / Change in cash | 1.94 Million | -6.54 Million | 1.56 Million | 1.65 Million | -4.09 Million | -1.38 Million |
| Free Cash Flow | -16.14 Million | -16.75 Million | -69.73 Million | -14.27 Million | -16.91 Million | -15.14 Million |
XELA
TRDA
0LPE
LASE
0220
EME